Good day,
We are excited to introduce you to a new way to receive The Early Bird's "Stock of the Day" a day before the stock idea shows up in The Early Bird's email newsletter.
Our free "Stock of the Day" service is delivered via SMS so that you can see each stock pick right away.
Each morning, you'll receive:
- Actionable stock picks, hand selected by MarketBeat's team of expert research analysts.
- Headlines and market insights for each selected ticker.
- A bull case and a bear case to help inform your next move.
- Timely updates and alerts so that you can capitalize quickly on each opportunity.
Ready to take your investing and trading to the next level?
Click Here to Receive The Early Bird's Stock of the Day (Free)
Best regards,
The Early Bird Team
3 Lesser-Known Healthcare Names With Major Upside in Store
Written by Nathan Reiff. Published 10/2/2025.
Key Points
- Healthcare is a massive, growing sector, but finding suitable investment targets can be a challenge—many companies are established and past their high-growth days, or early and highly risky for investors.
- Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio represent a category of healthcare stocks that may present a middle ground.
- These firms are established (to varying degrees) and have strong fundamentals, but still have ample growth trajectories.
The global healthcare market is expanding swiftly, with forecasts projecting a 6.9% compound annual growth rate through 2033 to exceed $22.3 trillion. Investors also value healthcare for its non-cyclical resilience, driven more by demographic and medical needs than by broader economic cycles.
Yet identifying healthcare stocks poised for substantial gains can be challenging. Many established players have already seen their rapid growth phases pass, while smaller names often remain speculative until they achieve a major commercial milestone or research breakthrough. The following firms strike a balance: they're not household names, but they boast solid fundamentals and meaningful upside potential.
Growing Revenue, Strong Product Lineup and Margins for Sanuwave
Nvidia CEO Makes First Ever Tesla Announcement (Ad)
While headlines focus on Tesla's car sales, tech analyst Jeff Brown says the real story is Tesla's role in a $25 trillion AI revolution — one that Nvidia's CEO himself has called a "multi-trillion-dollar future industry" — and he's uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.
Click here now to see the full reportSanuwave Health Inc. (NASDAQ: SNWV) develops non-invasive acoustic wave therapies for injury sites and other conditions. Although its market capitalization is under $300 million, the company delivered an impressive second-quarter report featuring an earnings surprise—analysts had forecast a per-share loss—and 42% year-over-year revenue growth.
Central to Sanuwave's lineup is the UltraMIST system, which uses ultrasound to accelerate wound healing. UltraMIST sales jumped 61% year over year in the latest quarter. The company's gross margin stands at 78.3%, and management anticipates further margin expansion as manufacturing costs decline.
Sanuwave's model combines one-time equipment sales with recurring, high-margin single-use consumables—driving a steady revenue stream and enhancing profitability.
Although only three Wall Street analysts cover SNWV, all are bullish. Their consensus price target sits about 59% above the current share price, indicating significant upside if the company maintains its growth trajectory.
Diversified Portfolio of Generics and More Drive Amneal's Appeal
Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) specializes in affordable medicines, from generics and biosimilars to government-distributed products. Earlier this year, the FDA approved Brekiya—a self-administered, non-refrigerated migraine treatment—adding to a robust pipeline.
In the second quarter, Amneal reported 23 cents in EPS—6 cents above estimates—with revenue up 3% year over year and adjusted EBITDA rising 13%. Strong sales of Crexont, Rytary and other products led Amneal to raise its full-year guidance.
While debt remains a consideration, Amneal refinanced $2.7 billion during the quarter, cutting annual interest costs by about $33 million. With a diversified product mix and improving financials, all five analysts covering AMRX rate it a Buy, projecting roughly 22% upside.
Clinical-Stage Biotech Targeting Unmet Needs
Belite Bio Inc. (NASDAQ: BLTE) is a clinical-stage firm developing therapies for nonalcoholic steatohepatitis (NASH), obesity and certain forms of macular degeneration. Its leading candidate, Tinlarebant, aims to address macular degeneration types that currently lack approved treatments.
Although pre-revenue, Belite finished the latest quarter with nearly $150 million in cash and continues to secure funding for its trials. Analysts are optimistic—four out of five rate BLTE a Buy, implying about 32% upside potential.
to bring you the latest market-moving news.
This message is a paid sponsorship for The Early Bird, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2025 MarketBeat Media, LLC dba TickerReport.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103-7078. USA..
Post a Comment
Post a Comment